相关实验视频
Updated: Feb 19, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
美国降血糖药物支出的国家趋势 患有糖尿病的成年人:2000-2022年
Yu Wang1, Kai McKeever Bullard1, Ping Zhang1
1Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
Diabetes care
|February 17, 2026
概括
美国患有糖尿病的成年人从2000年到2022年,血糖降低药物成本上升了335%. 这一增长是由新的,更昂贵的药物类别和更多的使用者推动的,这影响了糖尿病治疗总体支出.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 糖尿病管理 糖尿病管理
背景情况:
- 与糖尿病管理相关的医疗保健成本上升.
- 引入新的降血糖药物类别.
- 保险政策变化对处方药使用的影响.
研究的目的:
- 分析美国糖尿病成年人中人均消费降血糖药物的国家趋势.
- 检查2000年至2022年药品支出中的变化.
- 确定增加药物成本的驱动因素.
主要方法:
- 医学支出小组调查数据的分析 (2000-2022年).
- 按人口统计和保险状况分层的年人均支出计算.
- 利用结点回归来识别药品支出趋势变化.
主要成果:
- 人均总支出增长了335% (从856美元增加到3725美元).
- 2012年以后,由于新型非胰岛素药物推动,支出大幅加快.
- 更多地使用新的,更昂贵的疗法是增加开支的主要驱动因素.
结论:
- 人均支出大幅增加,用于购买新的糖尿病药物.
- 需要确定支出的主要驱动因素,以提高可负担性和可获得性.
- 在糖尿病药物治疗中节省成本策略的潜力.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Diabetes: Symptoms, Diagnosis, and Complications
2.4K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.4K
Diabetes Mellitus: Overview and Type I Subtype
5.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
698
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K

